Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
SAN LEANDRO, Calif.--(BUSINESS WIRE)--Feb 21, 2019--Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m. ET (10:30 a.m. PT) at the Lotte New York Palace in New York City.
About Rainier Therapeutics
Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic bladder cancer. The company’s antibody, vofatamab (formerly B-701), is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and other cancers. For more information, please visit www.rainierrx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005218/en/
CONTACT: Robert Uhl
KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: Rainier Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 02/21/2019 07:30 AM/DISC: 02/21/2019 07:31 AM